Fabio Ynoe de Moraes: A Study That Reflects Not Only Scientific Rigor, But Also Vision and Leadership
Fabio Ynoe de Moraes, Associate Professor at Queen’s University, shared Lucas C. Mendez’s post on LinkedIn:
“Amazing to see Dr. Lucas C. Mendez take the stage at ESTRO 2025 to present the primary endpoint results of the HOPE Trial — a study that reflects not only scientific rigor, but also vision and leadership in prostate cancer radiotherapy.
Watching colleagues lead clinical trials with real potential to change practice is a powerful reminder of why we do science: to create meaningful, evidence-based impact. Congratulations my friend for this outstanding achievement.
We move forward together, with hope grounded in evidence.”
Quoting Lucas C. Mendez’s post:
“ESTRO 2025 the primary endpoint results of the HOPE Trial. This is the first randomized trial I’ve been fortunate to lead and I feel very grateful for this opportunity. I am thankful to all collaborators, VFCC clinical research unit and especially, to all patients that have participated in this study. We trust this trial has the potential to impact practice and it has already impacted at London Health Sciences Centre (LHSC)”
More posts featuring Fabio Ynoe de Moraes.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023